🇺🇸 FDA

Company profile · Sponsor

Janssen

Janssen Cilag International NV

ED56C48 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Janssen (ED56C48) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ED56C48
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. Amivantamab

    Janssen

    Colorectal Neoplasms

    phase 3 mab active

    1 trial

  2. Apalutamide

    Janssen

    Metastatic Castrate-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  3. Canagliflozin

    Janssen

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  4. Cilta-cel

    Janssen

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. Dara SC

    Janssen

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  6. Daratumumab

    Janssen

    Multiple Myeloma

    phase 3 small molecule active

    3 trials

  7. Esketamine

    Janssen

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  8. Glimepiride

    Janssen

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  9. Golimumab 1 mg per kg

    Janssen

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial

  10. Guselkumab Dose 1

    Janssen

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  11. Ibrutinib

    Janssen

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  12. Icotrokinra

    Janssen

    Crohn Disease

    phase 3 small molecule active

    1 trial

  13. JNJ-77242113

    Janssen

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. LHRHa

    Janssen

    Prostatic Neoplasms

    phase 3 small molecule active

    1 trial

  15. Nipocalimab

    Janssen

    Sjogrens Syndrome

    phase 3 small molecule active

    1 trial

  16. Olanzapine

    Janssen

    Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  17. Paliperidone palmitate

    Janssen

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  18. Pimodivir 600 mg

    Janssen

    Influenza A

    phase 3 small molecule terminated

    1 trial

  19. Rituximab

    Janssen

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  20. Tapentadol IR 50 mg

    Janssen

    Hallux Valgus

    phase 3 small molecule completed

    1 trial

  21. Ustekinumab Dose Based on BSA and Body Weight

    Janssen

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  22. AL-335

    Janssen

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  23. Apalutamide

    Janssen

    Salivary Gland Neoplasms

    phase 2 small molecule active

    1 trial

  24. Azacitidine

    Janssen

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is Janssen?

Janssen (ED56C48) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Janssen sponsor?

We track 24 ClinicalTrials.gov-linked programs for Janssen, including Amivantamab and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Janssen company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.